No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection By Ogkologos - June 22, 2026 61 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR POT1 Mutations Associated with Long Telomere Length Confer a Predisposition to... May 17, 2023 An existing blood test for ovarian cancer has been re-evaluated. The... October 28, 2020 To My Fellow Nurses May 13, 2021 Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... September 26, 2022 Load more HOT NEWS Mark Hoppus Of Blink-182 Announces He’s Cancer-Free Patient Guide in Bladder Cancer Now Available Also in Italian Understanding Serving Sizes Community Surprises Teen Battling Bone Cancer With Brand New Car For...
